Hyloris Takes Maxigesic IV To South Korea And Panama

As Company Makes Progress With Regulatory Submission Process In US

After expanding the footprint of Maxigesic IV in several European countries, Hyloris has now received regulatory approvals for the non-opioid post-operative pain treatment in South Korea and Panama. The company remains focused on increasing the global footprint of Maxigesic IV in other countries, including the US. 

South Korea
Mayne Pharma markets more than twenty dermatology products in the US • Source: Alamy

Belgian value-added medicines specialist Hyloris Pharmaceuticals SA has announced receiving regulatory approvals for its Maxigesic IV (paracetamol/ibuprofen) 1,000mg/300mg non-opioid treatment for post-operative pain in South Korea and Panama.

Hyloris is planning to commence sales of Maxigesic IV in South Korea with licensing partner Kyongbo Pharmaceuticals, while Pharma Bavaria...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C7

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C6

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

US Biosimilars

An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.

Amneal Kicks Off China Business With First Approval

Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.

More from Generics Bulletin

GB-Business-Free-Podcast-The Secret to Walking More: It’s Not Counting Steps - Clone2 - Clone

 
• By 

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - Clone

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

GB-Business-Free-Podcast-The Secret to Walking More: It’s Not Counting Steps - Clone2

 
• By 

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.